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Abstract
Objective To evaluate the association between non-alcoholic fatty liver
disease and all cause and cause specific mortality in a representative
sample of the US general population.
Design Prospective cohort study.
Setting US Third National Health and Nutrition Examination Survey
(NHANES III: 1988-94) with follow-up of mortality to 2006.
Participants 11 371 adults aged 20-74 participating in the Third National
Health and Nutrition Examination Survey, with assessment of hepatic
steatosis.
Main outcome measure Mortality from all causes, cardiovascular
disease, cancer, and liver disease (up to 18 years of follow-up).
Results The prevalence of non-alcoholic fatty liver disease with and
without increased levels of liver enzymes in the population was 3.1%
and 16.4%, respectively. Compared with participants without steatosis,
those with non-alcoholic fatty liver disease but normal liver enzyme levels
had multivariate adjusted hazard ratios for deaths from all causes of
0.92 (95% confidence interval 0.78 to 1.09), from cardiovascular disease
of 0.86 (0.67 to 1.12), from cancer of 0.92 (0.67 to 1.27), and from liver
disease of 0.64 (0.12 to 3.59). Compared with participants without
steatosis, those with non-alcoholic fatty liver disease and increased liver
enzyme levels had adjusted hazard ratios for deaths from all causes of
0.80 (0.52 to 1.22), from cardiovascular disease of 0.59 (0.29 to 1.20),
from cancer of 0.53 (0.26 to 1.10), and from liver disease of 1.17 (0.15
to 8.93).
Conclusions Non-alcoholic fatty liver disease was not associated with
an increased risk of death from all causes, cardiovascular disease,
cancer, or liver disease.
Introduction
Non-alcoholicfattyliverdiseaseistheleadingcauseofchronic
liver disease in the United States and other Western countries,
with a prevalence as high as 30% in the general population.
1
Thediseaseencompassesawidespectrumofconditions,ranging
from steatosis to non-alcoholic steatohepatitis, fibrosis, and
cirrhosis.
2-6 Although non-alcoholic fatty liver disease can lead
to hepatocellular carcinoma
7 8 and is associated with several
cardiovascular risk factors,
9-14 its impact on mortality is
unknown. Results from studies on the association between
non-alcoholic fatty liver disease and mortality have been
inconsistent,
15-20 but these studies were limited by the use of
small, highly selected patient populations (for example, those
after liver biopsy) or by the use of liver enzyme measurements
as surrogate markers of non-alcoholic fatty liver disease.
21-23
Furthermore, since non-alcoholic fatty liver disease is strongly
associated with obesity and diabetes, whether it is an
independent risk factor for all cause and cardiovascular death
remainscontroversial,asmanypreviousstudiesfailedtoaccount
fully for adiposity.
We prospectively determined the association of non-alcoholic
fatty liver disease with mortality in the US general population.
We hypothesised that such disease would be associated with an
increased risk of mortality from all causes, cardiovascular
disease, cancer, and liver disease. We also hypothesised that
the risk of death would be higher in participants with
non-alcoholic fatty liver disease and increased liver enzyme
levels, potentially representing the presence of non-alcoholic
steatohepatitis.
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Results of sensitivity analyses
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We used data from the Third National Health and Nutrition
Examination Survey (NHANES III) and the Third National
Health and Nutrition Examination Survey Mortality Follow-up
studies. The Third National Health and Nutrition Examination
Survey was carried out from 1988 to 1994 using a complex,
multistage, stratified, clustered, probability sample design to
obtain a representative sample of the US population living in
households. The survey included an interview, physical
examination, and laboratory measurements (including
ultrasonographyofthegallbladder)in14797adultsaged20-74.
The mortality follow-up study was a prospective study of the
vital status of all participants aged 20 and older to December
2006. After exclusions, the analytical sample for the main
analyses included 11 371 adults. All participants signed
informed consent.
Data collection
The participants underwent an interview in which standardised
questionnaires were used to obtain self reported data on sex,
age, race or ethnicity, education, income, smoking, alcohol
consumption, physical activity, prevalent medical conditions,
anddruguse.
24Smokingstatuswascategorisedasnever,former,
and current smoker. History of cardiovascular disease was
definedasaselfreportedhistoryofacutemyocardialinfarction,
stroke, or heart failure. History of cancer was defined as a self
reported history of any cancer. People were categorised as
sedentary if they answered no to all the questions on engaging
in any of the following activities over the past month: jog or
run, cycle, swim, aerobics, other dancing, calisthenics, garden
or yard work, weight lifting, or other sports. Average daily
alcohol consumption was estimated by multiplying the number
of drinking days over the past 12 months and the number of
drinks,onaverage,onadrinkingdayanddividingby365.Never
drinkers replied no to the question: “In your entire life, have
you had at least 12 drinks of any kind of alcoholic beverage?”
Increased alcohol consumption was defined as one drink or
more daily among women and two drinks or more daily among
men.
25
Standardised measurements of height, weight, waist
circumference, and systolic and diastolic blood pressure were
obtained. Body mass index was calculated.
Serum biochemistries were done using the Hitachi 737
automated multichannel chemistry analyser (Boehringer
Mannheim Diagnostics, Indianapolis, IN).
26 Liver tests
determined levels of aspartate aminotransferase, alanine
aminotransferase, γ-glutamyltransferase, alkaline phosphatase,
and total bilirubin. The levels of alanine aminotransferase or
aspartate aminotransferase were considered raised if they were
above the upper limit of normal of the National Health and
Nutrition Examination Survey laboratory values (alanine
aminotransferase >40 U/L for men and >31 U/L for women;
aspartate aminotransferase >37 U/L for men and >31 U/L for
women).
26 The presence of antibodies to hepatitis C was tested
using a second generation enzyme immunoassay (Abbott
Laboratories, Chicago, IL) and confirmed by the MATRIX
assay (Abbott Laboratories). Antibodies to hepatitis B core
antigen were measured using a solid phase competitive
immunoassay(AbbottLaboratories).Serumironlevelsandtotal
iron binding capacity were measured calorimetrically (Alpkem
RFA analyzer, Clackamas, OR). Serum ferritin levels were
measured using the BioRad Quantimmune IRMA kit (BioRad
Laboratories, Hercules, CA). Serum transferrin saturation was
calculated as [serum iron (μmol/L)/serum total iron binding
capacity(μmol/L)]×100.Ironoverloadwasdefinedastransferrin
saturation greater than 45% and ferritin greater than 500 μg/L
among men and greater than 400 μg/L among women.
27 28
Assessment of hepatic steatosis
Ultrasound examinations on the gallbladder were carried out
ontheThirdNationalHealthandNutritionExaminationSurvey
participants aged 20 to 74 using a Toshiba (Tustin, CA)
SSA-90A machine using 3.75 and 5.0 MHz transducer.
29
Between 2009 and 2010, 13 856 (96.6%) of the archived
videotapes on gallbladder ultrasound examinations originally
obtained between 1988 and 1994 were reviewed to ascertain
the presence of fat within the hepatic parenchyma. A more
detailed description of the protocol can be found elsewhere.
30
Briefly, information was recorded on the presence of liver to
kidney contrast, degree of brightness of the liver parenchyma,
presenceofdeepbeamattenuation,presenceofechogenicwalls
inthesmallintrahepaticvessels,anddefinitionofthegallbladder
walls. Based on these findings and using a standardised
algorithm,
30 we categorised the degree of steatosis first as a four
level variable (none, mild, moderate, or severe steatosis) and
thenrecodedasatwolevelvariable:nonetomildandmoderate
tosevere.Theintra-raterandinter-raterκstatisticsforreliability
of the two level variable were 0.77 (95% confidence interval
0.73 to 0.82) and 0.70 (0.64 to 0.76), respectively.
30
Intheabsenceofastandarddefinition,wedefinednon-alcoholic
fatty liver disease as the presence of moderate to severe hepatic
steatosis with normal liver enzymes levels. Non-alcoholic
steatohepatitiswasdefinedasthepresenceofmoderatetosevere
hepatic steatosis with increased levels of liver enzymes, in the
absenceofantibodiestohepatitisBandhepatitisCandwithout
evidenceofironoverload.Forthenon-alcoholicsteatohepatitis
group we decided to exclude people with viral hepatitis B and
hepatitis C or with iron overload because these factors are
associated with increased liver enzyme levels.
Follow-up for mortality
To determine the vital status and cause of death, the National
CenterforHealthStatisticslinkedallparticipantsaged20years
and older to the National Death Index to 31 December 2006.
31
Therefore, for each participant follow-up extended from the
date of the examination to the date of death or 31 December
2006.
Causeofdeathwasdeterminedfromtheunderlyingcauselisted
on the death certificate. We used the publicly available linked
mortality data files, which identify the cause of death using the
Underlying Cause of Death-113 (UCOD 113) groups
(international classification of disease, 10th revision). The
Underlying Cause of Death-113 variable was created by the
National Center for Health Statistics to recode all deaths coded
under ICD-9 (international classification of disease, ninth
revision)—thatis,deathsbefore1999,intocomparableICD-10
groupstoassisttheresearcherwithanalysesthatspantheentire
survey period for mortality. The comparability of ICD-9 and
ICD-10 underlying cause of death UCOD 113 recode has been
validated (http://cdc.gov/nchs/data_access/data_linkage/
mortality/nhanes3_linkage.htm). We defined cardiovascular
diseasemortalityasdeathswithunderlyingcauseofdeathcodes:
ICD-10 I00-I69. Cancer mortality was defined as deaths with
underlying cause of death codes: ICD-10 C00-C-97. Finally,
liver related mortality was defined as deaths with underlying
cause of death codes: ICD-10 K-70, or K-73-K74.
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We compared the baseline characteristics of participants by
their hepatic steatosis status using Pearson χ
2 statistics for
categorical variables or Wald test for continuous variables.
Cumulative mortality was estimated using Kaplan-Meier
methods. Cox proportional hazards regression was used to
estimate hazard ratios and 95% confidence intervals for deaths
fromallcauses,cardiovasculardisease,cancer,andliverdisease
by hepatic steatosis status, with age as the timescale and
staggered entries into the study.
32 We used two models with
progressive degrees of adjustment: model 1 adjusted for sex
and race or ethnicity; model 2 further adjusted for education,
smoking, alcohol consumption, physical activity, body mass
index, hypertension, hypercholesterolaemia, and diabetes.
We carried out extensive sensitivity analyses: firstly, using an
alternative definition for non-alcoholic fatty liver disease that
further excluded participants with hepatitis C, hepatitis B, or
iron overload; secondly, including in the no steatosis group
(reference)participantswithhighalcoholconsumptionorusing
zydovudineordidanosinebutwithouthepaticsteatosis;thirdly,
excluding participants with a history of cardiovascular disease
or with history of cancer from the analyses of cardiovascular
deathandcancermortality;fourthly,excludingparticipantswho
died within the first year of follow-up for cancer mortality; and
fifthly, using alcohol consumption defined by UK safe limits
(14drinksaweekforwomenand21formen).Sixthly,toassess
the potential of misclassification of exposure, we carried out
anothersensitivityanalysiscomparingthegroupwithnohepatic
steatosis (that is, excluding those with mild steatosis) against
thosewithseverehepaticsteatosis(thatis,excludingthosewith
moderate steatosis).
Finallyweevaluatedtheassociationofnon-alcoholicfattyliver
diseaseandsteatohepatitiswithallcausemortalityforsubgroups
defined by sex, age, race or ethnicity, smoking status, body
massindexcategories,diabetes,andraisedγ-glutamyltransferase
levels. All analyses were done using Stata 11 and using the svy
commandstoaccountforthesamplingweightsandthecomplex
survey design.
Results
After exclusions (fig 1⇓), the analytical sample for the main
analyses included 11 371 adults aged 20-74 participating in the
Third National Health and Nutrition Examination Survey, with
assessment of hepatic steatosis. The overall prevalence of
non-alcoholicfattyliverdisease(excludingsteatohepatitis)and
steatohepatitis was 16.4% and 3.1%, respectively. Compared
with people without hepatic steatosis, participants with
non-alcoholic fatty liver disease were more likely to be older,
men, Mexican-American, less educated, sedentary, obese, to
have a high waist circumference, diabetes,
hypercholesterolaemia, hypertension, and a history of
cardiovascular disease, and less likely to be current smokers or
tohavelowtomoderatealcoholconsumption(table1⇓).People
with non-alcoholic fatty liver disease also had higher levels of
glycated haemoglobin, triglyceride:high density lipoprotein
cholesterol ratio, insulin resistance, and liver enzymes (alanine
aminotransferase, aspartate aminotransferase, and
γ-glutamyltransferase).Peoplewithnon-alcoholicsteatohepatitis
were similar to those with non-alcoholic fatty liver disease,
although slightly younger and with a slightly worse metabolic
risk profile (table 1).
The median follow-up was 14.5 (maximum 18.0) years. At the
end of follow-up, the cumulative mortality from all causes was
22.0% (1836 deaths). For cause specific deaths the cumulative
mortalitieswere10.9%forcardiovasculardisease(716deaths),
6.0% for cancer (480 deaths), and 0.5% for liver disease (44
deaths).
The risk of death from all causes in participants with
non-alcoholicfattyliverdiseaseornon-alcoholicsteatohepatitis
atbaselinewasnotincreasedcomparedwithparticipantswithout
hepatic steatosis (table 2⇓). After adjusting for
sociodemographic characteristics, lifestyle risk factors,
hypertension, and hypercholesterolaemia, the hazard ratios for
death when participants with non-alcoholic fatty liver disease
or non-alcoholic steatohepatitis were compared with those
without hepatic steatosis were 0.91 (95% confidence interval
0.78 to 1.08) and 0.80 (0.53 to 1.22), respectively (table 2). In
subgroups analyses, neither non-alcoholic fatty liver disease
nornon-alcoholicsteatohepatitiswereassociatedwithincreased
mortality in any subgroup (fig 2⇓).
For cause specific mortality, the fully adjusted hazard ratios in
people with non-alcoholic fatty liver disease or non-alcoholic
steatohepatitis compared with those without hepatic steatosis
were 0.86 (0.67 to 1.12) and 0.59 (0.29 to 1.20) for
cardiovascular disease, 0.92 (0.67 to 1.27) and 0.53 (0.26 to
1.10) for cancer, and 0.64 (0.12 to 3.59) and 1.17 (0.15 to 8.93)
for liver disease.
Similar findings resulted from sensitivity analyses excluding
from the referent group those participants with prevalent
cardiovascular disease, prevalent cancer, or deaths from cancer
occurring during the first year of follow-up, further excluding
participants with hepatitis C, hepatitis B, or iron overload from
the non-alcoholic fatty liver disease group, or not excluding
participants with high alcohol consumption or using
antiretrovirals(seewebextratables1and2).Sensitivityanalysis
with a different definition for high alcohol consumption
accordingtotheUKsafelimitsproducedalmostidenticalresults
(see web extra table 3). Finally, when participants with severe
steatosis were compared with those without steatosis the fully
adjusted hazard ratios for death from all causes were similar:
0.95 (0.73 to 1.25) and 0.75 (0.45 to 1.24), respectively (see
web extra table 4).
Discussion
In this nationally representative study in the United States, we
found no association between non-alcoholic fatty liver disease
or non-alcoholic steatohepatitis and deaths from all causes,
cardiovascular disease, cancer, or liver disease. These results
are important given the high prevalence of non-alcoholic fatty
liver disease in the general population and the concerns raised
by the adverse metabolic profile associated with this disease
and non-alcoholic steatohepatitis.
Comparison with other studies
Few studies have assessed the clinical course of non-alcoholic
fatty liver disease and its impact on mortality. Retrospective
studies of histology based non-alcoholic fatty liver disease and
mortality have been inconsistent. One study reported an
increased risk of death from all causes (standardised mortality
ratio compared with general Danish population of 2.6) among
1804 patients who had been admitted to the hospital and had a
discharge diagnosis of fatty liver; however, there was no
adjustment for potential confounders.
19 In contrast, two studies
thatusedbiopsyregistriestoidentifycasesoffattyliverdisease
found no evidence of an increased risk of death among patients
withnon-alcoholicfattyliverdiseasecomparedwiththegeneral
populationofeithertheUnitedKingdomorDenmark.
16 20These
authors were not able to adjust for confounders either. More
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RESEARCHrecently, a study followed up a cohort of 144 patients with
biopsy confirmed non-alcoholic fatty liver disease referred for
evaluation of persistently raised liver enzyme levels, thus
representingamoreseverespectrumofnon-alcoholicfattyliver
disease than the current study. Over 13.7 years of follow-up,
patients with non-alcoholic fatty liver disease had similar
survival to the general Swedish population (matched for age
and sex), although the risk of death was increased in patients
with non-alcoholic steatohepatitis.
18 Finally, a study
15
retrospectively identified 420 patients with non-alcoholic fatty
liver disease and found a 34% increased risk of death in this
group compared with the general Minnesota population over
7.6yearsoffollow-up.Thehighlyselectednatureofthepatient
population in these studies, including the use of patients with
access to medical care who underwent liver biopsy as part of
investigations,makesitdifficulttodrawfirmconclusionsabout
theimpactofnon-alcoholicfattyliverdiseaseandnon-alcoholic
steatohepatitis on mortality in the population as a whole.
To our knowledge only three studies have evaluated the
association between non-alcoholic fatty liver disease and
mortality in samples from the general population.
21-23 These
studies used data from the Third National Health and Nutrition
Examination Survey, but all used liver enzyme levels as
surrogate markers of non-alcoholic fatty liver disease, and
follow-up extended only to 2000. These three studies used
different definitions of non-alcoholic fatty liver disease (all
based on liver enzyme levels) and most of them adjusted for
potential confounders. One of these studies defined
non-alcoholic fatty liver disease as a raised alanine
aminotransferase level in the absence of high alcohol
consumption or increased transferrin saturation, hepatitis B, or
hepatitis C and found no increased risk for all cause mortality.
Another study using a similar definition of non-alcoholic fatty
liverdiseasefurtherrestrictedthestudytoparticipantsnottaking
a large number of potentially hepatotoxic drugs and reported a
37% increase in mortality for those with non-alcoholic fatty
liver disease (P=0.07). Finally, another study found that people
with raised levels of alanine aminotransferase in the absence of
hepatitis B or hepatitis C were not at increased risk of death
from all causes (hazard ratio of 1.2) or cardiovascular disease
(hazard ratio of 0.90). All of these studies found an increased
risk of liver related death for people with raised liver enzyme
levels.
Contrary to our hypotheses and to current belief
14 and despite
a clear and strong association between non-alcoholic fatty liver
disease and diabetes, insulin resistance, and obesity, our study
did not find an association between non-alcoholic fatty liver
disease or non-alcoholic steatohepatitis and deaths from all
causes,cardiovasculardisease,cancer,orliverdisease.Although
other outcomes related to non-alcoholic fatty liver disease,
including cirrhosis, cancer, and a more rapid progression of
coexistentliverdiseasesmaybeimportant,ourfindingssupport
the suggestion that people with accumulation of fat in the liver
haveagoodprognosiswithrespecttomortality.Onespeculation
is that the ability of the liver to store triglycerides may in fact
be a protection mechanism in obesity.
33 In the absence of such
a response, free fatty acids may accumulate and lead to more
severe liver damage and systemic consequences.
34
Strengths and limitations of the study
Ultrasonography is widely used to detect hepatic steatosis at
the population level and, as shown in a recent meta-analysis,
can accurately detect non-alcoholic fatty liver disease (pooled
sensitivity of 84.8% and specificity of 93.6%).
35 However, for
non-alcoholic steatohepatitis in the absence of liver biopsy we
used increases in the liver enzyme levels alanine
aminotransferase or aspartate aminotransferase in the presence
of steatosis to define non-alcoholic steatohepatitis. Although
we ruled out other potential and common causes of raised liver
enzyme levels, such as viral hepatitis, iron overload, and high
alcohol consumption, we are aware that this definition has a
limited sensitivity and specificity,
36 and thus our results for
non-alcoholicsteatohepatitisshouldbeinterpretedwithcaution.
Further studies with large samples and more refined diagnostic
methods for non-alcoholic steatohepatitis are needed to
determine the effect of steatohepatitis on mortality.
We had only a single measure of non-alcoholic fatty liver
disease, which could not capture changes in hepatic steatosis
over time, resulting in non-differential misclassification. We
used data on education, smoking, alcohol consumption, and
physical activity, but these data are generally collected based
on self report. We had a limited sample size to study cause
specificdeathsassociatedwithnon-alcoholicfattyliverdisease.
Although the follow-up was longer than in previous studies, it
may be too short to assess the effect of non-alcoholic fatty liver
disease on liver related mortality, given the time it takes for
liver disease to progress. Finally, we were unable to study the
association between non-alcoholic fatty liver disease and
non-fatalcomplications.Inthefuture,largermulticollaborative
studies, such as the Nonalcoholic Steatohepatitis-Clinical
Research Network
37 should be encouraged to comprehensively
and extensively study the association between non-alcoholic
fatty liver disease, non-alcoholic steatohepatitis, and other
non-fatal outcomes.
Ourstudyalsohasnotablestrengths.TheThirdNationalHealth
and Nutrition Examination Survey and the associated mortality
follow-up study represent the only nationally representative
sample with results for liver imaging and long term mortality
(up to 18 years). The participants are well characterised, with
extensive laboratory and physical examination and
measurements of hepatic steatosis. Finally, data were collected
by trained staff following rigorous, standardised protocols to
ensure that measurement errors were minimised.
Conclusions and implications
In conclusion, we found no association between ultrasound
defined non-alcoholic fatty liver disease and deaths from all
causes, cardiovascular disease, cancer, or liver disease in the
USpopulation.Theseresultshaveimportantimplicationssince
non-alcoholic fatty liver disease is the most common liver
diseaseinthepopulationandisreceivingconsiderableattention
asanindependentriskfactorforcardiovasculardisease.
14Since
stage of the disease is likely to be a critical determinant of the
overall prognosis, our findings need to be confirmed with
improved non-invasive assessment tools and finer staging of
non-alcoholicfattyliverdiseaseinthegeneralpopulation.None
the less, our results indicate that although non-alcoholic fatty
liver disease is strongly associated with cardiovascular risk
factors, such patients are not at increased risk of death from all
causes or cardiovascular disease.
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Table 1| Baseline characteristics of study sample from Third National Health and Nutrition Examination Survey (1988-94) by hepatic steatosis
status. Values are percentages (standard errors) of participants unless stated otherwise
P value
Non-alcoholic steatohepatitis
(n=426)
Non-alcoholic fatty liver
disease (n=2089)
No hepatic steatosis
(n=8856) Characteristics
<0.001 42.9 (1.2) 48.3 (0.6) 41.4 (0.4) Mean (SE) age (years)
0.001 54.1 (4.5) 52.4 (1.3) 45.6 (0.7) Men
≤0.001 Race or ethnicity:
71.8 (2.9) 76.8 (1.7) 76.4 (1.5) Non-Hispanic white
5.9 (1.0) 8.9 (0.9) 10.9 (0.7) Non-Hispanic black
13.8 (2.0) 6.2 (0.7) 4.9 (0.4) Mexican-American
<0.001 64.6 (4.1) 64.8 (2.2) 54.9 (1.2) <12 years education
<0.001 Body mass index:
0.9 (0.8) 1.6 (0.4) 2.5 (0.3) <18.5
11.8 (2.7) 17.6 (1.7) 47.9 (1.1) 18.5-24.9
27.5 (4.6) 36.1 (1.7) 32.3 (0.6) 25-29.9
26.4 (3.4) 25.8 (1.2) 12.2 (0.5) 30-34.9
33.5 (4.2) 19.0 (1.4) 5.0 (0.6) ≥35
<0.001 77.3 (4.0) 66.2 (1.9) 29.9 (1.0) High waist circumference*
<0.001 21.3 (3.5) 15.8 (1.0) 5.4 (0.4) Diabetes†
<0.001 38.4 (4.4) 35.7 (1.9) 19.7 (0.8) Hypertension‡
<0.001 48.3 (4.4) 38.2 (2.0) 28.5 (0.8) Hypercholesterolaemia§
<0.001 25.2 (3.6) 26.4 (1.6) 19.3 (0.9) Sedentary
<0.001 6.3 (1.5) 8.2 (0.8) 3.7 (0.3) History of cardiovascular disease
0.32 6.3 (2.1) 7.7 (0.9) 6.1 (0.5) History of cancer
<0.001 16.1 (3.8) 22.7 (1.4) 28.4 (0.9) Current smoking
<0.001 Alcohol consumption:
11.2 (2.1) 15.9 (1.2) 13.0 (0.7) Never
88.8 (2.1) 84.1 (1.2) 87.0 (0.7) Low-moderate
<0.001 6.0 (0.2) 5.7 (0.04) 5.3 (0.02) Mean (SE) glycated haemoglobin (%)
<0.001 69.1 (5.8) 52.6 (2.9) 23.8 (1.1) Raised triglyceride levels¶
<0.001 6.9 (0.9) 4.7 (0.2) 2.8 (0.06) Mean (SE) triglycerides:high density
lipoprotein cholesterol ratio¶
<0.001 79.2 (5.7) 54.4 (3.0) 19.6 (0.9) Insulin resistance¶**
<0.001 54.1 (2.7) 18.6 (0.4) 16.3 (0.3) Mean (SE) alanine aminotransferase (U/L)
<0.001 44.1 (2.2) 20.4 (0.1) 20.4 (0.1) Mean (SE) aspartate aminotransferase
(U/L)
<0.001 79.1 (6.6) 31.3 (1.0) 25.0 (0.5) Mean (SE) γ-glutamyltransferase (U/L††)
*>102 cm (men) and >88 cm (women).
†Self reported doctor diagnosis, drug use, fasting plasma glucose concentration ≥7.0 mmol/L or random plasma glucose concentration ≥11 mmol/L.
‡Self reported doctor diagnosis, drug use, systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg.
§Self reported doctor diagnosis, drug use, or total cholesterol concentration >6.2 mmol/L.
¶Fasting (n=5066), and homeostatic model assessment-insulin resistance (HOMA-IR) >2.86 (above fourth quartile among people without diabetes).
**Among people without diabetes (n=4660).
††Among random subset of participants (n=8975).
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RESEARCHTable 2| Risk of death from all causes, cardiovascular disease, cancer, and liver disease in people with non-alcoholic fatty liver disease
and non-alcoholic steatohepatitis compared with those with no hepatic steatosis, Third National Health and Nutrition Examination Survey
(1988-94)
Hazard ratio (95% CI)
No hepatic steatosis (n=8856) Unweighted No Non-alcoholic steatohepatitis (n=426) Non-alcoholic fatty liver disease (n=2089)
All cause mortality:
57 469 1310 No of events
0.95 (0.62 to 1.47) 1.04 (0.89 to 1.21) 1 (reference) Model 1*
0.80 (0.52 to 1.22) 0.92 (0.78 to 1.09) 1 (reference) Model 2†
Cardiovascular disease mortality:
16 192 508 No of events
0.88 (0.43 to 1.80) 1.08 (0.84 to 1.38) 1 (reference) Model 1*
0.59 (0.29 to 1.20) 0.86 (0.67 to 1.12) 1 (reference) Model 2†
Cancer mortality:
14 116 350 No of events:
0.49 (0.25 to 0.95) 0.91 (0.68 to 1.22) 1 (reference) Model 1*
0.53 (0.26 to 1.10) 0.92 (0.67 to 1.27) 1 (reference) Model 2†
Liver disease mortality:
3 7 34 No of events:
1.67 (0.26 to 10.60) 0.89 (0.20 to 4.01) 1 (reference) Model 1*
1.17 (0.15 to 8.93) 0.64 (0.12 to 3.59) 1 (reference) Model 2†
*Adjusted for sex and race.
†Further adjusted for education, smoking, alcohol consumption, physical activity, body mass index, hypertension, hypercholesterolaemia, and diabetes.
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Fig 1 Flow of participants through study
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RESEARCHFig 2 Subgroup analyses of association between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis with all
cause mortality
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